Acuta Capital Partners, LLC Syndax Pharmaceuticals Inc Transaction History

Acuta Capital Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $40,743 - $61,086	-2,806 Reduced 0.94%	297,035 $4.31 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $583,576 - $672,847	-30,159 Reduced 9.14%	299,841 $6.28 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $111,274 - $156,086	5,386 Added 1.66%	330,000 $6.97 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $2.21 Million - $2.97 Million	119,611 Added 58.35%	324,614 $7.8 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $15,317 - $21,876	-1,123 Reduced 0.54%	205,003 $3.94 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $658,304 - $1.24 Million	-49,054 Reduced 19.22%	206,126 $3.54 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $4.05 Million - $5.17 Million	-210,320 Reduced 45.18%	255,180 $5.71 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $3.39 Million - $5.94 Million	224,756 Added 93.36%	465,500 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $2.15 Million - $5.05 Million	240,744 New	240,744 $3.57 Million

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $910M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.